Amyloid Copathology
Showing 1 - 25 of 607
Clearance Mechanisms in Atypical Neurodegenerative Diseases
Not yet recruiting
- Neurodegenerative Diseases
- Frontotemporal Degeneration
-
München, Bayern, GermanyKlinik und Poliklinik für Psychiatrie und Psychotherapie des LMU
Mar 31, 2022
Lumbar Spine Stenosis Specimens for Identification of
Not yet recruiting
- Lumbar Spinal Stenosis
- +5 more
- Tc99-PYP or Tc99-HDMP Scan
-
Beverly Hills, California
- +5 more
Sep 12, 2023
Samples and Clinical Data From Patients With Amyloid Diseases
Recruiting
- Multiple Myeloma
- clonality analysis
- +6 more
-
Boston, MassachusettsBoston University Cancer Research Center
Jan 28, 2023
Database to Investigate Blood-Based and Digital Biomarkers in
Recruiting
- Alzheimer Disease
- +5 more
- Biomarker Data Collection
-
Aventura, Florida
- +15 more
Sep 21, 2022
Hypertension Trial in Dallas (Standard Care, Intensive Treatment)
Active, not recruiting
- Hypertension
- Standard Care
- Intensive Treatment
-
Dallas, TexasUT Southwestern Medical Center
Aug 11, 2022
Alzheimer Trial in Boston (Transcranial Alternating Current Stimulation (tACS))
Completed
- Alzheimer Disease
- Transcranial Alternating Current Stimulation (tACS)
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Aug 18, 2022
Amyloidosis Trial in Berkeley, Sacramento, San Jose (I124-AT01 only)
Active, not recruiting
- Amyloidosis
- I124-AT01 only
-
Berkeley, California
- +2 more
Sep 12, 2022
Alzheimer Trial in United States (AV-1959D, Placebo)
Not yet recruiting
- Alzheimer Disease
- AV-1959D
- Placebo
-
Phoenix, Arizona
- +5 more
Dec 22, 2022
Program to Identify Participants at High Risk for Amyloid
Not yet recruiting
- Alzheimer's Disease
- No Intervention
-
Lady Lake, Florida
- +1 more
Sep 12, 2023
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology) Trial in Ann Arbor (PET Biomarker Disclosure)
Enrolling by invitation
- Mild Cognitive Impairment
- Dementia; Alzheimer's Type (Etiology)
- PET Biomarker Disclosure
-
Ann Arbor, MichiganUniversity of Michigan Medical School, Department of Psychiatry
Jan 11, 2023
Alzheimer Trial in Berlin, Munich (DSPE-DOTA-Gd Liposomal Injection)
Recruiting
- Alzheimer Disease
- DSPE-DOTA-Gd Liposomal Injection
-
Berlin, Germany
- +1 more
Jul 12, 2022
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range
Recruiting
- Heart Failure With Reduced Ejection Fraction
- +3 more
- Dapagliflozin 10mg Tab
- Placebo
-
Moscow, Russian FederationNational Medical Research Center for Cardiology, Ministry of Hea
Mar 20, 2023
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
Active, not recruiting
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Cardiac MRI
-
Boston, Massachusetts
- +10 more
Oct 4, 2023
Mild Cognitive Impairment, Alzheimer Trial in United States (Donanemab, Aducanumab)
Active, not recruiting
- Mild Cognitive Impairment
- Alzheimer Disease
-
Fullerton, California
- +30 more
Jan 18, 2023
Learn About Tafamidis in Transthyretin Amyloid Cardiomyopathy in
Not yet recruiting
- Transthyretin Amyloid Cardiomyopathy
- (no location specified)
Oct 11, 2023
Systemic Amyloidosis Trial in Knoxville (99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.,
Recruiting
- Systemic Amyloidosis
- 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.
- 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.
-
Knoxville, TennesseeUniversity of Tennessee Graduate School of Medicine
Jul 10, 2023
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Trial in Indianapolis, Boston (Eplontersen)
Recruiting
- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
-
Indianapolis, Indiana
- +19 more
Jan 31, 2023
Alzheimer Trial in United States (Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care)
Not yet recruiting
- Alzheimer Disease
- Anti-amyloid Monoclonal Antibodies (mAbs)
- Standard of Care
-
Albany, Georgia
- +7 more
Aug 13, 2023
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction
Recruiting
- AD
- +2 more
-
Shanghai, ChinaHuashan Hospital
May 8, 2022
Heart Disease, Aging, Amyloidosis Trial in France (a basal LV septum biopsy)
Active, not recruiting
- Heart Disease
- +3 more
- a basal LV septum biopsy
-
Creteil, France
- +5 more
Sep 30, 2022
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
Completed
- Mild Cognitive Impairment
-
New York, New YorkWeill Cornell Medicine
Oct 18, 2022